Sreenivas Gannavaram
Overview
Explore the profile of Sreenivas Gannavaram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boussoffara T, Labidi I, Trimeche M, Chelbi I, Dachraoui K, Msallem N, et al.
NPJ Vaccines
. 2025 Feb;
10(1):31.
PMID: 39952958
Dogs are the main reservoir host of Leishmania infantum, etiological agent of zoonotic visceral leishmaniasis (ZVL). An effective vaccine against Canine Visceral Leishmaniasis (CVL) will help the control and elimination...
2.
Sepahpour T, Alshaweesh J, Azodi N, Singh K, Ireland D, Valanezhad F, et al.
NPJ Vaccines
. 2024 Dec;
9(1):250.
PMID: 39702382
Leishmaniasis is a tropical disease caused by Leishmania parasites and currently has no licensed vaccines. We developed a dermotropic Leishmania major centrin gene-deleted strain (LmCen) as a live attenuated vaccine....
3.
Avishek K, Beg M, Vats K, Singh A, Dey R, Singh K, et al.
Sci Rep
. 2024 Jun;
14(1):14636.
PMID: 38918456
Centrin1 gene deleted Leishmania donovani parasite (LdCen1) was developed and extensively tested experimentally as an intracellular stage-specific attenuated and immunoprotective live parasite vaccine candidate ex vivo using human PBMCs and...
4.
Avendano-Rangel F, Agra-Duarte G, Borba P, Moitinho V, Avila L, da Silva L, et al.
Vaccines (Basel)
. 2024 Mar;
12(3).
PMID: 38543944
Immunization with various species lacking induces robust immunity against a homologous and heterologous virulent challenge, making mutants a putative candidate for a leishmaniasis vaccine. Centrin is a calcium-binding cytoskeletal protein...
5.
Kaldhone P, Azodi N, Markle H, Dahiya N, Stewart C, Anderson J, et al.
Microorganisms
. 2024 Feb;
12(2).
PMID: 38399684
Violet-blue light of 405 nm in the visible spectrum at a dose of 270 J/cm alone has been shown to be an effective microbicidal tool for inactivating several bacteria, HIV-1,...
6.
Volpedo G, Oljuskin T, Cox B, Mercado Y, Askwith C, Azodi N, et al.
iScience
. 2023 Dec;
26(12):108502.
PMID: 38125023
Cutaneous leishmaniasis (CL) is characterized by extensive skin lesions, which are usually painless despite being associated with extensive inflammation. The molecular mechanisms responsible for this analgesia have not been identified....
7.
Dey R, Alshaweesh J, Singh K, Lypaczewski P, Karmakar S, Klenow L, et al.
Nat Commun
. 2023 Nov;
14(1):7028.
PMID: 37919280
The leishmanin skin test was used for almost a century to detect exposure and immunity to Leishmania, the causative agent of leishmaniasis, a major neglected tropical disease. Due to a...
8.
Volpedo G, Pacheco-Fernandez T, Oljuskin T, Markle H, Azodi N, Hamano S, et al.
iScience
. 2023 Sep;
26(9):107594.
PMID: 37744404
Leishmaniasis is a tropical disease prevalent in 90 countries. Presently, there is no approved vaccine for human use. We developed a live attenuated strain as a vaccine candidate that showed...
9.
Oljuskin T, Azodi N, Volpedo G, Bhattacharya P, Markle H, Hamano S, et al.
iScience
. 2023 Sep;
26(9):107593.
PMID: 37744403
Leishmaniasis is a parasitic disease that is prevalent in 90 countries, and yet no licensed human vaccine exists against it. Toward control of leishmaniasis, we have developed gene deletion mutant...
10.
Karagiannis K, Gannavaram S, Verma C, Pacheco-Fernandez T, Bhattacharya P, Nakhasi H, et al.
Cell Rep
. 2023 Sep;
42(9):113097.
PMID: 37682713
Although phagocytic cells are documented targets of Leishmania parasites, it is unclear whether other cell types can be infected. Here, we use unbiased single-cell RNA sequencing (scRNA-seq) to simultaneously analyze...